The Administrative Core (Core A) is an essential core that will coordinate and provide appropriate administrative support for all three projects and the other three cores in this PPG. The Core will provide administrative support for the PI of this Core and the PPG (Dr. Dario Vignali) and will be located in Department of Immunology at the University of Pittsburgh School of Medicine, Pittsburgh, USA. In the first ~4 years of this program, Core A established a centralized and transparent organizational structure to coordinate all scientific aspects of the PPG and resolve any conflicts or issues. We have increased the role of the Core to promote training, education and collaboration among trainees. This Core will pursue two aims:
AIM 1 : To provide collaborative and educational support for the program. Core A will continue to support and promote collaborative and educational efforts by performing the following four key tasks. (1) Maintain IR- PPG Box account. (2) Organize monthly meetings. (3) Promote education and training. (4) Coordinate annual PPG retreat and ESAG.
AIM 2 : To provide administrative support for the program. Administrative support and coordination will be provided through seven key tasks. (1) Monitor progress on Projects and use of Cores. (2) Prepare non- competitive renewal applications/progress reports. (3) Provide budgetary management and fiscal, regulatory, and compliance oversight. (4) Coordinate resource sharing. (5) Authentication of key resources. (6) Verification of manuscript submission to PubMed Central. (7) Conflict resolution. PPG Interactions: Core A will work extensively with Projects 1, 2, and 3 to provide administrative and organizational support, monitoring progress, and hosting data and presentations. The Core will also help coordinate Cores B, C, and D by providing a platform for data sharing, monitoring usage and productivity, and managing budgetary responsibilities. Lastly, it will organize meetings and retreats.

Public Health Relevance

The inhibitory receptors PD1 and LAG3 synergize to limit autoimmune disease. However, they are also over expressed in cancer and chronic viral infections, preventing disease clearance. Although PD1 and LAG3 are now major therapeutic targets, it is not clear how they mediated this synergistic regulation and on which cells types. A greater understanding of these issues could lead to move effective therapeutic strategies. Core A will provide administrative and statistical support to all projects and cores and is essential.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
2P01AI108545-06
Application #
10023664
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2015-05-15
Project End
2025-07-31
Budget Start
2020-06-01
Budget End
2021-05-31
Support Year
6
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15260
Overacre-Delgoffe, Abigail E; Vignali, Dario A A (2018) Treg Fragility: A Prerequisite for Effective Antitumor Immunity? Cancer Immunol Res 6:882-887
Stelekati, Erietta; Chen, Zeyu; Manne, Sasikanth et al. (2018) Long-Term Persistence of Exhausted CD8 T Cells in Chronic Infection Is Regulated by MicroRNA-155. Cell Rep 23:2142-2156
Bengsch, Bertram; Ohtani, Takuya; Khan, Omar et al. (2018) Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity 48:1029-1045.e5
Ratay, Michelle L; Glowacki, Andrew J; Balmert, Stephen C et al. (2017) Treg-recruiting microspheres prevent inflammation in a murine model of dry eye disease. J Control Release 258:208-217
Huang, Alexander C; Postow, Michael A; Orlowski, Robert J et al. (2017) T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545:60-65
Hope, Jennifer L; Stairiker, Christopher J; Spantidea, Panagiota I et al. (2017) The Transcription Factor T-Bet Is Regulated by MicroRNA-155 in Murine Anti-Viral CD8+ T Cells via SHIP-1. Front Immunol 8:1696
Andrews, Lawrence P; Marciscano, Ariel E; Drake, Charles G et al. (2017) LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev 276:80-96
Chen, Zeyu; Stelekati, Erietta; Kurachi, Makoto et al. (2017) miR-150 Regulates Memory CD8 T Cell Differentiation via c-Myb. Cell Rep 20:2584-2597
Zhang, Qianxia; Chikina, Maria; Szymczak-Workman, Andrea L et al. (2017) LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes. Sci Immunol 2:
Kurachi, Makoto; Kurachi, Junko; Chen, Zeyu et al. (2017) Optimized retroviral transduction of mouse T cells for in vivo assessment of gene function. Nat Protoc 12:1980-1998

Showing the most recent 10 out of 21 publications